Get the Stockscreener App
32.56
7.87%
-2.78
After Hours:
32.96
0.40
+1.23%
Neurogene Inc stock is traded at $32.56, with a volume of 229.73K.
It is down -7.87% in the last 24 hours and up +22.91% over the past month.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
See More
Previous Close:
$35.34
Open:
$35.23
24h Volume:
229.73K
Relative Volume:
1.32
Market Cap:
$514.51M
Revenue:
$925.00K
Net Income/Loss:
$-98.64M
P/E Ratio:
-6.4872
EPS:
-5.0191
Net Cash Flow:
$-83.37M
1W Performance:
+0.87%
1M Performance:
+22.91%
6M Performance:
+77.92%
1Y Performance:
+62.07%
1-Day Range:
$32.42
$36.03
1-Week Range:
$30.34
$36.03
52-Week Range:
$15.93
$37.27
Neurogene Inc Stock (NGNE) Company Profile
Name
Neurogene Inc
Sector
Industry
Phone
(877) 237-5020
Address
535 W 24TH STREET, NEW YORK
Compare NGNE vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NGNE
Neurogene Inc
|
32.56 | 496.97M | 925.00K | -98.64M | -83.37M | -5.0191 |
VRTX
Vertex Pharmaceuticals Inc
|
529.59 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.81 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.80 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.99 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Neurogene Inc Stock (NGNE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-17-25 | Initiated | Craig Hallum | Buy |
| May-16-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-27-24 | Initiated | BMO Capital Markets | Outperform |
| Jun-11-24 | Initiated | Robert W. Baird | Outperform |
| Apr-29-24 | Initiated | Leerink Partners | Outperform |
| Mar-21-24 | Initiated | William Blair | Outperform |
| Jan-08-24 | Initiated | H.C. Wainwright | Buy |
| Jan-05-24 | Initiated | Stifel | Buy |
| Jan-04-24 | Initiated | TD Cowen | Outperform |
View All
Neurogene Inc Stock (NGNE) Latest News
Form 424B5 Neurogene Inc For: 2 July By Investing.com - Investing.com Canada
Neurogene (NGNE) secures $134.8M, extending cash runway into 2029 - Stock Titan
Citizens reiterates Taysha Gene Therapies stock rating on therapy progress By Investing.com - Investing.com Canada
Leerink raises Neurogene stock price target to $77 on Rett data - Investing.com South Africa
Neurogene Inc. Stock 12‑Month Price Target Raised to $79.62, Implies 153% Upside - TradingView
Neurogene prices $125 million public offering at $30 per share - Investing.com
Neurogene prices $125M equity offering - MSN
Why is Neurogene stock sliding today? By Investing.com - Investing.com Canada
Neurogene Prices $125 Million Public Offering - marketscreener.com
Neurogene prices $125 million public offering at $30 per share By Investing.com - Investing.com Canada
Neurogene locks in $125M stock sale, closing expected July 2 - Stock Titan
Form 424B5 Neurogene Inc For: 30 June - Investing.com UK
Neurogene commences public offering of common stock - scanx.trade
Neurogene stock falls on public offering announcement - Investing.com UK
Neurogene stock falls on public offering announcement By Investing.com - Investing.com South Africa
Neurogene launches public stock offering - MSN
Neurogene Inc Files For Offering Of Common Stock, Pre-Funded Warrants To Buy Common Stock Size Not DisclosedSEC Filing - TradingView
Neurogene Launches Public Offering - marketscreener.com
Neurogene Inc. (NGNE) files to offer common stock and pre-funded warrants - Stock Titan
Neurogene launches public offering of common stock - Investing.com
Neurogene launches public offering of common stock By Investing.com - Investing.com Canada
Neurogene Inc. Announces Proposed Public Offering - marketscreener.com
H.C. Wainwright reiterates Neurogene stock rating on trial data - Investing.com UK
H.C. Wainwright reiterates Neurogene stock rating on trial data By Investing.com - Investing.com South Africa
Canaccord reiterates Neurogene stock rating on Rett syndrome data By Investing.com - Investing.com Nigeria
Neurogene reports 47 milestone gains in NGN-401 trial - grafa.com
Neurogene reports milestone gains in Rett syndrome gene therapy trial By Investing.com - Investing.com India
$32.506 | Neurogene Inc. Common Stock (NGNE) Stock Price Today - Binance
Neurogene reports promising long-term NGN-401 Rett data - TipRanks
Neurogene reports durable Phase 1/2 NGN-401 gains: 47 milestones across 10 patients, Embolden topline due 2H 2027 - TradingView
Rett gains: Neurogene (NASDAQ: NGNE) shows durable NGN-401 milestone data - Stock Titan
Neurogene Says Phase 1/2 NGN-401 Data Show Progressive Improvements in Rett Syndrome - marketscreener.com
Neurogene (NGNE) Reports Positive Phase 1/2 Trial Results for NG - GuruFocus
Neurogene reports milestone gains in Rett syndrome gene therapy trial - Investing.com
Neurogene says Rett gene therapy drove 47 milestones in 10 patients - Stock Titan
Price to sales forward of Neurogene Inc. – NASDAQ:NGNE - TradingView
Enterprise value to EBIT forward of Neurogene Inc. – NASDAQ:NGNE - TradingView
Enterprise value to EBITDA forward of Neurogene Inc. – NASDAQ:NGNE - TradingView
Enterprise value to EBITDA forward of Neurogene Inc. – BOATS:NGNE - TradingView
Price to earnings forward of Neurogene Inc. – BOATS:NGNE - TradingView
Neurogene (NGNE) Q4 2025 earnings summary - Quartr
Neurogene (NGNE) Stifel 2026 Virtual CNS Forum Summary - Quartr
Neurogene (NGNE) Q1 2026 earnings summary - Quartr
This $20 Biotech Stock Just Got An FDA Boost – And A $200 Price Target - Stocktwits
UU8 Forecast — Price Target — Prediction for 2027 - TradingView
Neurogene Inc. Actuals & Estimates (NASDAQ:NGNE) - TradingView
NGNE Q1 2026 Earnings: EPS Misses Estimates as Clinical Advances ContinueSubscription Growth Report - dars.gov.et
NGNE Forecast — Price Target — Prediction for 2027 - TradingView
NGNE SEC FilingsNeurogene 10-K, 10-Q, 8-K Forms - Stock Titan
NGNE Q1 2026 Earnings: Wider-than-Expected Loss Weighed Against Pipeline ProgressShort-Term Outlook - dars.gov.et
Neurogene Inc (NGNE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Neurogene Inc Stock (NGNE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Neurogene Inc Stock (NGNE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Cvijic Christine Mikail | President and CFO |
Jul 01 '26 |
Sale |
34.06 |
739 |
25,170 |
92,901 |
| Cvijic Christine Mikail | President and CFO |
May 06 '26 |
Sale |
31.25 |
9,600 |
300,043 |
93,640 |
0.05%
0.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):